American Society of Hematology Annual Meeting Sessions On-Demand 2023
Format: 262 videos + 1193 pdfs, size: 96.7 GB
Course Audience: hematologist
Overview:
The American Society of Hematology (ASH) Annual Meeting 2023 was a premier event in classical and malignant hematology. It provided an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
The webcasts from the 65th ASH Annual Meeting and Exposition are now available. These webcasts provide access to more than 400 hours of recorded content from the meeting, including oral abstract sessions.
Education Program Acquired Hemophilia A Diagnosis and Management Andreas Tiede-24122 (PDF Format)
Education Program Acquired Hemophilia A Diagnosis and Management Rebecca Kruse-Jarres-24122 (PDF Format)
Education Program Acquired Hemophilia A Diagnosis and Management Sean Platton-24122 (PDF Format)
Education Program Acquired Hemophilia A Diagnosis and Management (Video TS Format)
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Ashish Kumar-24117 (PDF Format)
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Clifford Takemoto-24117 (PDF Format)
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Nicole Kucine-24117 (PDF Format)
Education Program Alphabet Soup – Challenging Consults on the Pediatric Units (Video TS Format)
Education Program Are We Personalizing MDS Therapy in 2023 David Sallman-24106 (PDF Format)
Education Program Are We Personalizing MDS Therapy in 2023 Marie Sebert-24106 (PDF Format)
Education Program Are We Personalizing MDS Therapy in 2023 Rena Xian-24106 (PDF Format)
Education Program Are We Personalizing MDS Therapy in 2023 (Video TS Format)
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Alice Bertaina-24107 (PDF Format)
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Nirali Shah-24107 (PDF Format)
Education Program CAR T Cells in ALL Bridge or Definitive Therapy Stephen Gottschalk-24107 (PDF Format)
Education Program CAR T Cells in ALL Bridge or Definitive Therapy (Video TS Format)
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Eduard Van Beers-24125 (PDF Format)
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Kevin Kuo-24125 (PDF Format)
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Rachael Grace-24125 (PDF Format)
Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias (Video TS Format)
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kasiani Myers-24118 (PDF Format)
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kristen Schratz-24118 (PDF Format)
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Suneet Agarwal-24118 (PDF Format)
Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right (Video TS Format)
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Idoroenyi Amanam-24100 (PDF Format)
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Kirk Schultz-24100 (PDF Format)
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Muna Qayed-24100 (PDF Format)
Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure (Video TS Format)
Education Program Have We Optimized Therapy Yet for Patients with AML Justin Watts-24104 (PDF Format)
Education Program Have We Optimized Therapy Yet for Patients with AML Tara Lin-24104 (PDF Format)
Education Program Have We Optimized Therapy Yet for Patients with AML (Video TS Format)
Education Program Hematologic Toxicity of Immunotherapies Frederick Locke-24113 (PDF Format)
Education Program Hematologic Toxicity of Immunotherapies Martin Hutchings-24113 (PDF Format)
Education Program Hematologic Toxicity of Immunotherapies Michael Kroll-24113 (PDF Format)
Education Program Hematologic Toxicity of Immunotherapies (Video TS Format)
Education Program Hematologists and the Care of Pregnant Women Adam Lewkowitz-24121 (PDF Format)
Education Program Hematologists and the Care of Pregnant Women Andra James-24121 (PDF Format)
Education Program Hematologists and the Care of Pregnant Women Fionnuala Ni Ainle-24121 (PDF Format)
Education Program Hematologists and the Care of Pregnant Women (Video TS Format)
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Adi Zoref-Lorenz-24124 (PDF Format)
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Martin Tallman-24124 (PDF Format)
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Steven Fein-24124 (PDF Format)
Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies (Video TS Format)
Education Program Hemostasis in Patients With Severe Liver Disease Lara Roberts-24123 (PDF Format)
Education Program Hemostasis in Patients With Severe Liver Disease Ton Lisman-24123 (PDF Format)
Education Program Hemostasis in Patients With Severe Liver Disease Walter Ageno-24123 (PDF Format)
Education Program Hemostasis in Patients With Severe Liver Disease (Video TS Format)
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Darja Karpova-24119 (PDF Format)
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Mindy Goldman-24119 (PDF Format)
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Richard Kaufman-24119 (PDF Format)
Education Program Hot Topics in Blood Donation Donor Risks and Social Justice (Video TS Format)
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Dipti Patel-Donnelly-24110 (PDF Format)
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Jesus Berdeja-24110 (PDF Format)
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Ruemu Birhiray-24110 (PDF Format)
Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community (Video TS Format)
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Nizar Bahlis-24102 (PDF Format)
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Sham Mailankody-24102 (PDF Format)
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Surbhi Sidana-24102 (PDF Format)
Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies (Video TS Format)
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Anna Maria Sureda Balari-24097 (PDF Format)
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Loretta Nastoupil-24097 (PDF Format)
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Manali Kamdar-24097 (PDF Format)
Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 (Video TS Format)
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Anita DSouza-24112 (PDF Format)
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Deepti Radia-24112 (PDF Format)
Education Program How Do We Enhance Results in Rare Hematologic Malignancies Oussama Abla-24112 (PDF Format)
Education Program How Do We Enhance Results in Rare Hematologic Malignancies (Video TS Format)
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Chaitra Ujjani-24111 (PDF Format)
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Joanna Rhodes-24111 (PDF Format)
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Toby Eyre-24111 (PDF Format)
Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 (Video TS Format)
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Adam Cohen-24103 (PDF Format)
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Francesca Gay-24103 (PDF Format)
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Monique Hartley-Brown-24103 (PDF Format)
Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 (Video TS Format)
Education Program How Do We Tackle Remaining Clinical Challenges in CML Massimo Breccia-24109 (PDF Format)
Education Program How Do We Tackle Remaining Clinical Challenges in CML Naranie Shanmuganathan-24109 (PDF Format)
Education Program How Do We Tackle Remaining Clinical Challenges in CML Simona Soverini-24109 (PDF Format)
Education Program How Do We Tackle Remaining Clinical Challenges in CML (Video TS Format)
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Andrew Evens-24098 (PDF Format)
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Natalie Grover-24098 (PDF Format)
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Sairah Ahmed-24098 (PDF Format)
Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 (Video TS Format)
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Adetola Kassim-24127 (PDF Format)
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle John Tisdale-24127 (PDF Format)
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Kenneth Ataga-24127 (PDF Format)
Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle (Video TS Format)
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Emma Groarke-24126 (PDF Format)
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Marena Niewisch-24126 (PDF Format)
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Timothy Olson-24126 (PDF Format)
Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult (Video TS Format)
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Emily Curran-24108 (PDF Format)
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL John Molina-24108 (PDF Format)
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Tamara Miller-24108 (PDF Format)
Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL (Video TS Format)
Education Program Ongoing Challenges in the Management of VTE Cecilia Becattini-24115 (PDF Format)
Education Program Ongoing Challenges in the Management of VTE Keith McCrae-24115 (PDF Format)
Education Program Ongoing Challenges in the Management of VTE Kenneth Bauer-24115 (PDF Format)
Education Program Ongoing Challenges in the Management of VTE (Video TS Format)
Education Program The Iron Revolution Jacquelyn Powers-24116 (PDF Format)
Education Program The Iron Revolution Michael Auerbach-24116 (PDF Format)
Education Program The Iron Revolution Thomas Deloughery-24116 (PDF Format)
Education Program The Iron Revolution (Video TS Format)
Education Program Transfusion Support in Sickle Cell Disease Anoosha Habibi-24120 (PDF Format)
Education Program Transfusion Support in Sickle Cell Disease France Pirenne-24120 (PDF Format)
Education Program Transfusion Support in Sickle Cell Disease Shannon Kelly-24120 (PDF Format)
Education Program Transfusion Support in Sickle Cell Disease (Video TS Format)
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Douglas Tremblay-24099 (PDF Format)
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Harinder Gill-24099 (PDF Format)
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Jeanne Palmer-24099 (PDF Format)
Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management (Video TS Format)
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Alison Walker-24105 (PDF Format)
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Jacqueline Cloos-24105 (PDF Format)
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Marion Subklewe-24105 (PDF Format)
Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML (Video TS Format)
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Asmita Mishra-24101 (PDF Format)
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Reena Jayani-24101 (PDF Format)
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Roni Shouval-24101 (PDF Format)
Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together (Video TS Format)
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Jennifer McIntosh-24114 (PDF Format)
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Shruti Chaturvedi-24114 (PDF Format)
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies TBD Retter-24114 (PDF Format)
Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies (Video TS Format)
General Sessions ASH-EHA Joint Symposium Alexander Medvinsky-24135 (PDF Format)
General Sessions ASH-EHA Joint Symposium Linheng Li-24135 (PDF Format)
General Sessions ASH-EHA Joint Symposium (Video TS Format)
General Sessions E. Donnall Thomas Lecture and Prize Katayoun Rezvani-24174 (PDF Format)
General Sessions E. Donnall Thomas Lecture and Prize (Video TS Format)
General Sessions Ernest Beutler Lecture and Prize Johnny Mahlangu-24175 (PDF Format)
General Sessions Ernest Beutler Lecture and Prize Takehisa Kitazawa-24175 (PDF Format)
General Sessions Ernest Beutler Lecture and Prize (Video TS Format)
General Sessions Ham-Wasserman Lecture Andreas Greinacher-24133 (PDF Format)
General Sessions Ham-Wasserman Lecture (Video TS Format)
General Sessions Late Breaking Abstracts Adetola Kassim-25508 (PDF Format)
General Sessions Late Breaking Abstracts Hamish Scott-25508 (PDF Format)
General Sessions Late Breaking Abstracts Ibrahim Aldoss-25508 (PDF Format)
General Sessions Late Breaking Abstracts Keith McCrae-25508 (PDF Format)
General Sessions Late Breaking Abstracts Michael Wang-25508 (PDF Format)
General Sessions Late Breaking Abstracts Pieter Sonneveld-25508 (PDF Format)
General Sessions Late Breaking Abstracts (Video TS Format)
General Sessions Plenary Scientific Session Banu Aygun-25390 (PDF Format)
General Sessions Plenary Scientific Session Betty Pace-25390 (PDF Format)
General Sessions Plenary Scientific Session Brian Krum-25390 (PDF Format)
General Sessions Plenary Scientific Session Daniel Wolff-25390 (PDF Format)
General Sessions Plenary Scientific Session Francesca Gay-25390 (PDF Format)
General Sessions Plenary Scientific Session Isaac Odame-25390 (PDF Format)
General Sessions Plenary Scientific Session Pamela Ting-25390 (PDF Format)
General Sessions Plenary Scientific Session Peter Voorhees-25390 (PDF Format)
General Sessions Plenary Scientific Session Salima Benbarche-25390 (PDF Format)
General Sessions Plenary Scientific Session Stefanie Sarantopoulos-25390 (PDF Format)
General Sessions Plenary Scientific Session Stephanie Halene-25390 (PDF Format)
General Sessions Plenary Scientific Session Trista North-25390 (PDF Format)
General Sessions Plenary Scientific Session (Video TS Format)
General Sessions Presidential Symposium Claudia Kemper-24134 (PDF Format)
General Sessions Presidential Symposium Eleni Gavriilaki-24134 (PDF Format)
General Sessions Presidential Symposium Lubka Roumenina-24134 (PDF Format)
General Sessions Presidential Symposium (Video TS Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Hsiang-Ying Lee-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Lei Yu-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Marlies Rossmann-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Meng Zhang-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Vincent Schulz-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Xiurui Lv-24504 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation (Video TS Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rajesh Gunage-24503 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rebecca Griffiths-24503 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Xu Han-24503 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yajing Chu-24503 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yuefeng Tang-24503 (PDF Format)
Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease (Video TS Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Caroline Philpott-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Gayle Ross-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Ilona Kleine Budde-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Rachel Josselsohn-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Tomas Ganz-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Veena Sangkhae-24505 (PDF Format)
Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis (Video TS Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Alfonso Fernandez-24506 (PDF Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Eugene Khandros-24506 (PDF Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Ginette Balbin-Cuesta-24506 (PDF Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Pinyaphat Khamphikham-24506 (PDF Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Yu Wang-24506 (PDF Format)
Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia (Video TS Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Auria Godard-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Boya Liu-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Britney Hernandez-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Luisanna Sanchez Ventura-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Mira Pochron-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Scott Peslak-24507 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease (Video TS Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Anton Ilich-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Christopher Chambliss-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Jason Sutin-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Malgorzata Kasztan-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Marissa Traets-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Suruchi Salgar-24508 (PDF Format)
Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans (Video TS Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Alan Anderson-24511 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Angela Rankine-Mullings-24511 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Pablo Pelinski-24511 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Robyn Cohen-24511 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Sophie Lanzkron-24511 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation (Video TS Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Miguel Abboud-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Modupe Idowu-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Nirmish Shah-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Santosh Saraf-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Shubaya Naggayi-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Swee Lay Thein-24512 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease (Video TS Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Anna Sowa-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Dunia Hatabah-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Julie Kanter-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mariane De Montalembert-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mehndi Dandwani-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Modupe Idowu-24509 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors (Video TS Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Clare Zarka-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Jackie Queen-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Justin Yoo-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Kristine Karkoska-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Martha Kenney-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Ryan Sun-24510 (PDF Format)
Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future (Video TS Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Adi Zoref-Lorenz-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Chen Li-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Coralie Bloch-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Misato Komori-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Ningning Zhang-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Peter Dimitrion-24514 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes (Video TS Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Christina Simoglou Karali-24513 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Danielle Arnold-24513 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Malte Ritter-24513 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Vahagn Makaryan-24513 (PDF Format)
Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias (Video TS Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Benjamin Babcock-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Carlos Bravo-Perez-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Dandan Wang-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Francesco Saettini-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Mei Yu-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Melissa Mavers-24515 (PDF Format)
Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity (Video TS Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Anish Sharda-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Huichun Zhan-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Junmei Chen-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Kelsey Sack-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Luke Dunaway-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Nilesh Pandey-24518 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis (Video TS Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Adam Kanack-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Caitlin Schneider-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Cristobal Rivera-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Meghna Naik-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Moua Yang-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Yvonne Kong-24517 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis (Video TS Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Anthony Washington-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Harvey Roweth-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Heng Mei-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Jianlin Qiao-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Lauren Murphy-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Yuxiu Chen-24516 (PDF Format)
Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias (Video TS Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Ahmad Tarawah-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anna Frandsen-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anne Juhl-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes David Kuter-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Elizabeth King-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Hanny Al-Samkari-24521 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes (Video TS Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Catherine Broome-24519 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Michael Tarantino-24519 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Min Xu-24519 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Nichola Cooper-24519 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Yun Wang-24519 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia (Video TS Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Bertrand Godeau-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Cy Wilkins-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Etienne Crickx-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Taylor Kim-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yoann Zadro-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yuxiu Chen-24520 (PDF Format)
Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations (Video TS Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Aleksandr Shamanaev-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Lucas Van Gorder-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Meng-Ni Fan-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Shekhar Kumar-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Thomas Girard-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Wenjing Cao-24522 (PDF Format)
Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies (Video TS Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Davide Matino-24525 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Evelien Krumb-24525 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Guy Young-24525 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Marilyn Manco-Johnson-24525 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Yeu-Chin Chen-24525 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care (Video TS Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Allison Wheeler-24523 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Ferdows Atiq-24523 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Lynn Malec-24523 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Steven Pipe-24523 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan (Video TS Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Aditi Sharma-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Anthony Chan-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Ellen Zhang-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Eva Leinoe-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Rachel Kronenfeld-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Valentina Restrepo-24524 (PDF Format)
Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders (Video TS Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Kenki Saito-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marie Scully-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marissa Schraner-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Maryam Subhan-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Omid Peyvandi-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Senthil Sukumar-24526 (PDF Format)
Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations (Video TS Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Bec (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Jus (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Kri (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care She (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Sim (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care (Video TS Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Amelia Haj-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Gary Woods-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Julie Jaffray-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Justine Ryu-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Sacha Belinda Mapombo Choupa-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Vilmarie Rodriguez-24528 (PDF Format)
Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism (Video TS Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Lise McQuilten-24529 (PDF Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Matthew Tanner-24529 (PDF Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Nanyan Zhang-24529 (PDF Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Patricia Davenport-24529 (PDF Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Slim Azouzi-24529 (PDF Format)
Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine (Video TS Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alejandro Roisman-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alison Livada-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Helen Wang-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Stephanie Hurwitz-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Takao Yogo-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Tanner Martinez-24781 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness (Video TS Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Aditya Barve-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Karolina Vanickova-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Maegan Capitano-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Md Akram Hossain-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Virginia Camacho-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Yiran Meng-24530 (PDF Format)
Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress (Video TS Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Lynn Quek-24532 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Nikolaos Sousos-24532 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Saravanan Ganesan-24532 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Sean Wen-24532 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries (Video TS Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Adriana Chiaramida-24531 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations J. Beeler-24531 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Johannes Damm-24531 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Nicole Prutsch-24531 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Yifan Zhou-24531 (PDF Format)
Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations (Video TS Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Charles Ayemoba-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Dinisha Kamble-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Eman Khatib-Massalha-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Irene Ganan-Gomez-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Rheanna Congdon-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Shoichiro Takeishi-24533 (PDF Format)
Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease (Video TS Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Bhavisha Patel-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carlos Bravo-Perez-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carmelo Gurnari-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Masanori Yoshida-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Pedro Prata-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Yoshitaka Zaimoku-24535 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment (Video TS Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Antonio Risitano-24534 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Austin Kulasekararaj-24534 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Carlos de Castro-24534 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Fengkui Zhang-24534 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Jens Panse-24534 (PDF Format)
Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials (Video TS Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc .Kendra Jackson-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Johan Flygare-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Mona M.Hosseini-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Seth Rotz-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Valeria Visconte-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Y. Lucy Liu-24536 (PDF Format)
Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. (Video TS Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Bac Viet Le-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Chun-Wei Chen-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Qingyu Luo-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Thomas Koehnke-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xiangguo Shi-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xin He-24538 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (Video TS Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Ayana Kon-24537 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Cailin Collins-24537 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jane Xu-24537 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jie Bai-24537 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jonny Mendoza-Castrejon-24537 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy (Video TS Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Dorien Pastoors-24539 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Luca Nunzio Cifarelli-24539 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Madeline Niederkorn-24539 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Prajwal Boddu-24539 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Yu-Hsuan Chang-24539 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics (Video TS Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Amanda Tajik-24540 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Cl‚ment Larrue-24540 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Daiki Karigane-24540 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Junya Sango-24540 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Sarah Skuli-24540 (PDF Format)
Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms (Video TS Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Darko Barisic-24541 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Gabriel Brisou-24541 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Mirca Saurty-Seerunghen-24541 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Ruifeng Sun-24541 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Sergio Roa-24541 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis (Video TS Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression I-Jun Lau-24542 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Marta Fernandes-24542 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Nataly Cruz-Rodriguez-24542 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Qi Jin-24542 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Vera Poort-24542 (PDF Format)
Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression (Video TS Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Claudia Cabrera-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Eric Vick-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Karanpreet Bhatia-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Lei Zhang-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Sana Chaudhry-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Tim Kong-24545 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies (Video TS Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Kedwin Ventura-24543 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Li Du-24543 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Priyanka Sharma-24543 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Satoshi Kaito-24543 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Zhixiang Chen-24543 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies (Video TS Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Anagha Sheth-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Juan Jose Rodriguez Sevilla-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Vincent Rondeau-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Xinyue Zhou-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yi Zhang-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yuki Nishida-24544 (PDF Format)
Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (Video TS Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Damian Green-24546 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Keito Suto-24546 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Leandro Cerchietti-24546 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Nathan Beals-24546 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Selina Chen-Kiang-24546 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma (Video TS Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Britten Gordon-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Giulia Veltri-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Gregory Crimmins-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Jasmeet Sidhu-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Qin Li-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Thomas Lew-24547 (PDF Format)
Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias (Video TS Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Aman Wadhwa-24548 (PDF Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Motohiro Kato-24548 (PDF Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Noam Kopmar-24548 (PDF Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Sarah Elitzur-24548 (PDF Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Stuart Winter-24548 (PDF Format)
Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL (Video TS Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Curtis Lachowiez-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Enrico Attardi-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Pinkal Desai-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Rabea Mecklenbrauck-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Vikram Dhillon-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Wajma Shahbaz-24549 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related (Video TS Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Erika Cattaneo-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Georgina Gener-Ricos-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Himachandana Atluri-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Matthew Schwede-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Riya Sinha-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Xin Wang-24550 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI (Video TS Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Alex Bataller-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Constance Baer-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Marius Bill-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Niek Van Der Maas-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Richard Aplenc-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Yazan Abu-Shihab-24551 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication (Video TS Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Cameron Hunter-24552 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches David Grinblatt-24552 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches James Foran-24552 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Talha Badar-24552 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Zofia Gross-24552 (PDF Format)
Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches (Video TS Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jayastu Jain-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jonathan Webster-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Marlise Luskin-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicola Goekbuget-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicolas Boissel-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Wanda Salzer-24554 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL (Video TS Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Karen Rabin-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Martin Schrappe-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Nicola Goekbuget-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Sabina Chiaretti-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Tanja Gruber-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Xiaoyuan Gong-24553 (PDF Format)
Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL (Video TS Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML B. Smith-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Harry Erba-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Himachandana Atluri-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Hunault-Berger Mathilde-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Jing Lu-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Xiaohui Suo-24555 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML (Video TS Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Andrew Moore-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Fabio Guolo-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Franco Locatelli-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Kristoffer Hellstrand-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Li Gao-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Luca Guarnera-24557 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL (Video TS Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexander Perl-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexandre Kadia-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Gertjan Kaspers-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Nigel Russell-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Xiaoping Liang-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Yunxiang Zhang-24556 (PDF Format)
Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML (Video TS Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Guillaume Richard-Carpentier-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Harinder Gill-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Leo Ruhnke-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Musa Yilmaz-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Naval Daver-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Sylvain Garciaz-24558 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents (Video TS Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Elias Jabbour-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Ghayas Issa-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Li Yang-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Robert Zeiser-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Sara Zarnegar-Lumley-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Yuchen Liu-24559 (PDF Format)
Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Eduardo Magalhaes-24564 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Fanny Gonzales-24564 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Nastassja Scheidegger-24564 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Ramprasad Ramakrishnan-24564 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics V‚ronique Lisi-24564 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Andrew Stiff-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Diego Pereira-Martins-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Francisco Marchi-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Juan Barajas-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Martina Pigazzi-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Yotaro Ochi-24561 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Bettina Nadorp-24562 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Danielle Kirkey-24562 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Isabel Weinhaeuser-24562 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Sergio Rutella-24562 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Chong Chyn Chua-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Corentin Orvain-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Gege Gui-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jacqueline Cook-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jad Othman-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Maddalena Benetton-24563 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Adrian Mosquera Orgueira-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Curtis Lachowiez-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Mark Levis-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Pierre Peterlin-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Romane Joudinaud-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Shai Shimony-24560 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant (Video TS Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Adriane Halik-24565 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Gregor Hoermann-24565 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Hussein Abbas-24565 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Sander Lambo-24565 (PDF Format)
Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response (Video TS Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Hanna Thorsson-24566 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Ilaria Iacobucci-24566 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Jingliao Zhang-24566 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Lorenz Bastian-24566 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Shunsuke Kimura-24566 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis (Video TS Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Anna Gurevich Shapiro-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Francesco Corrado-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Guranda Chitadze-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Satoshi Yoshimura-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Sean Tracy-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Willem Cox-24567 (PDF Format)
Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment (Video TS Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alan Cooper-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alicia Beyou-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Andrew Feldman-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics James Phelan-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Natasha Lewis-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Sandrine Roulland-24568 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics (Video TS Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Alexis Claudel-24569 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Fabrice Jardin-24569 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Julia Paczkowska-24569 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Kyoko Yamaguchi-24569 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Tomohiro Aoki-24569 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc (Video TS Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Joseph Schroers-Martin-24570 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Pantaleo De Simone-24570 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Reid Merryman-24570 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Wen-Hsuan Wendy Lin-24570 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Xiyue Xu-24570 (PDF Format)
Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma (Video TS Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Dylan Tatterton-24573 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jon Arnason-24573 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jose A. Martinez-Climent-24573 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Ken Young-24573 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Yusuke Isshiki-24573 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma (Video TS Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Ilja Kalashnikov-24572 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Kanutte Huse-24572 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Matias Autio-24572 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Vignesh Shanmugam-24572 (PDF Format)
Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma (Video TS Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Franck Morschhauser-24574 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Jonathan Friedberg-24574 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Lorenzo Falchi-24574 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Stephen Schuster-24574 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy (Video TS Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emanuele Zucca-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emmanuel Bachy-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Jillian Gunther-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Loic Ysebaert-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Morgane Cheminant-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Yucai Wang-24577 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL (Video TS Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Anita Kumar-24576 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Carlo Visco-24576 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Craig Portell-24576 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Eliza Hawkes-24576 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Michael Wang-24576 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents (Video TS Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Clementine Sarkozy-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Jonathon Cohen-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Juan Alderuccio-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Paolo Strati-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Umberto Vitolo-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Vincent Ribrag-24575 (PDF Format)
Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy (Video TS Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Catherine Diefenbach-24580 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Elizabeth Phillips-24580 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Hun Lee-24580 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Jeremy Abramson-24580 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma (Video TS Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Eric Jacobsen-24578 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Seok Jin Kim-24578 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Steven Horwitz-24578 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Yuqin Song-24578 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas (Video TS Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Alison Moskowitz-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Jonathan Brammer-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Pierluigi Porcu-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sanjal Desai-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sarah Rutherford-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Thais Fischer-24579 (PDF Format)
Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas (Video TS Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Adam Olszewski-24582 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Clementine Sarkozy-24582 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jason Westin-24582 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jillian Simard-24582 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Lorenzo Falchi-24582 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas (Video TS Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Charalambos Andreadis-24583 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Christopher Melani-24583 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Gerhard Held-24583 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Martin Hutchings-24583 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Sabarish Ayyappan-24583 (PDF Format)
Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Chan Cheah-24584 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Elizabeth Lihua Budde-24584 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Emil Kyvsgaard-24584 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Peter Riedell-24584 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Trent Wang-24584 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jelena Jelicic-24585 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jinhua Liang-24585 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jordan Goldstein-24585 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Mark Roschewski-24585 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Norbert Schmitz-24585 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Aung Tun-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Gloria Iacoboni-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Jean Koff-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Loretta Nastoupil-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Sanjal Desai-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Viktoriya Zelikson-24588 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Arushi Khurana-24589 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Brian Sworder-24589 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Fabian Frontzek-24589 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Pallawi Torka-24589 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Steven Bair-24589 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Andrew Zelenetz-24586 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Rena Buckstein-24586 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Shinpei Harada-24586 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient (Video TS Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Bhausaheb Bagal-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL David Hodgson-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Evelyn Orlando-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Kathryn Lurain-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Monica Balzarotti-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Steven Durani-24587 (PDF Format)
Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL (Video TS Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jennifer O Sullivan-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jyoti Nangalia-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Marc Usart-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Matthew Stubbs-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Vignir Helgason-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Yuki Tahira-24591 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery (Video TS Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Billy Truong-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Charlotte Brierley-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Joseph Kim-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Molly Brakhane-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Nicole Vincelette-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Tim Kong-24590 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models (Video TS Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Golam Mohi-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Isabelle Becker-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Koki Ueda-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Madeline Caduc-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Naseer Basma-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Warren Fiskus-24592 (PDF Format)
Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context (Video TS Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches David Yeung-24593 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Fadi Haddad-24593 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Jorge Cortes-24593 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Qian Jiang-24593 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Timothy Hughes-24593 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches (Video TS Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Andreas Hochhaus-24594 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Franck Nicolini-24594 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Frederic Millot-24594 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Susan Branford-24594 (PDF Format)
Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication (Video TS Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Harinder Gill-24595 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Naveen Pemmaraju-24595 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Sanjay Mohan-24595 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Srinivas Tantravahi-24595 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Steffen Koschmieder-24595 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies (Video TS Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Lindsay Rein-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Nico Gagelmann-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Pankit Vachhani-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Raajit Rampal-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Rithin Nedumannil-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Yu-Hung Wang-24597 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers (Video TS Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Andrew Kuykendall-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Elliot Stieglitz-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Matthieu Groh-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Prithviraj Bose-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Sudipto Mukherjee-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Tsewang Tashi-24598 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies (Video TS Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Deepika Dilip-24596 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Ellen Ritchie-24596 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Joachim Goethert-24596 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Justin Watts-24596 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Trine Knudsen-24596 (PDF Format)
Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs (Video TS Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Carmelo Gurnari-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications He Tian (Tony) Chen-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Martina Sarchi-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Noah Salama-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Srinivas Aluri-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Zohar Sachs-24599 (PDF Format)
Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications (Video TS Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Elsa Bernard-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Johann-Christoph Jann-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Julia Montoro-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Luca Lanino-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Rurika Okuda-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Tariq Kewan-24600 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS (Video TS Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Cristina Astrid Tentori-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Guillermo Garcia-Manero-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Maria Diez-Campelo-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Moshe Mittelman-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Rami Komrokji-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Sandra Huber-24603 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS (Video TS Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Daniel Nguyen-24601 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Douglas Tremblay-24601 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jacqueline Garcia-24601 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jan Philipp Bewersdorf-24601 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Lok Lam Ngai-24601 (PDF Format)
Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS (Video TS Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Billy Jebaraj-24604 (PDF Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Claudio Martines-24604 (PDF Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Laura Polcik-24604 (PDF Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Prajish Iyer-24604 (PDF Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Yi Miao-24604 (PDF Format)
Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation (Video TS Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Armin Riecke-24606 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Jennifer Brown-24606 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Moritz Furstenau-24606 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Othman Al-Sawaf-24606 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Sarka Pavlova-24606 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation (Video TS Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Andy Rawstron-24605 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Carol Follows-24605 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Jeff Sharman-24605 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Paolo Ghia-24605 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Peter Hillmen-24605 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia (Video TS Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Constantine Tam-24607 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Brown-24607 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Woyach-24607 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Parag Jasani-24607 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Tanya Siddiqi-24607 (PDF Format)
Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Georgina Anderson-24613 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Laura Lucia Cogrossi-24613 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Luz Moreno Rueda-24613 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Yakinthi Chrisochoidou-24613 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Zachary Hunter-24613 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Elizabeth Lightbody-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Faith Davies-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Hsiling Chiu-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Ross Firestone-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Takahiro Kamiya-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Xiaoli Mi-24608 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Deeksha Vishwamitra-24610 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Fumou Sun-24610 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Mansour Poorebrahim-24610 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Maximilian Merz-24610 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Ram Pillarisetti-24610 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Eugenio Morelli-24609 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marcella Kaddoura-24609 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marios Papadimitriou-24609 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Rodger Tiedemann-24609 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Wataru Kuroki-24609 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Anthony Cirrincione-24612 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Camila Guerrero-24612 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Elizabeth Lightbody-24612 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Yubin Kang-24612 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions (Video TS Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Itziar Cenzano-24611 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Marc-Andrea Baertsch-24611 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Minghao Dang-24611 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Saurabh Zanwar-24611 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Visanu Wanchai-24611 (PDF Format)
Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Alireza Tafazzol-24616 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Benjamin Diamond-24616 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Chunrui Li-24616 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Sahar Khan-24616 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Yeasung Lee-24616 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Carmen Gonzalez-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Elizabeth Hill-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Febe Smits-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Nizar Bahlis-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Tadeusz Kubicki-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Yael Cohen-24620 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Carolina Schinke-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Daniel Wong-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Evangelos Terpos-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Martin Kaiser-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Theresia Akhlaghi-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Wenqiang Deng-24618 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Chakra Chaulagain-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Cristina Perez-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Efstathios Kastritis-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Jon Thorir Oskarsson-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Michael Wysota-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Santiago Thibaud-24617 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Gaurav Agarwal-24615 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Nisha Joseph-24615 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Noemi Puig-24615 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Yered Pita-Juarez-24615 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Darren Pan-24614 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Doris Hansen-24614 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Elise Cellerin-24614 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Michel Delforge-24614 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Sridevi Rajeeve-24614 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma (Video TS Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Aintzane Zabaleta-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Danai Dima-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Darren Pan-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Junia Vieira dos Santos-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Michel Delforge-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Xiang Zhou-24619 (PDF Format)
Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications (Video TS Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Ajai Chari-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Hang Quach-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Jeffrey Matous-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Paul Richardson-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Sumit Madan-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Wee-Joo Chng-24623 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma (Video TS Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Cyrille Touzeau-24622 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Maria-Victoria Mateos-24622 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Niels van de Donk-24622 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Ola Landgren-24622 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Omar Nadeem-24622 (PDF Format)
Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma (Video TS Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Efstathios Kastritis-24624 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Jahanzaib Khwaja-24624 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Moshe Gatt-24624 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Thorir Einarsson Long-24624 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Xin Jiang-24624 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis (Video TS Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Mackenzie Maberry-24625 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Nickolas Tsakmaklis-24625 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Shayna Sarosiek-24625 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Szymon Szymura-24625 (PDF Format)
Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders (Video TS Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Aditiya Rayasam-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Albert Yeh-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Chi Nguyen-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Dongchang Zhao-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Kristina Mott-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Marco Calafiore-24626 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome (Video TS Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Andri Leo Lemarquis-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution David Granadier-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Fathima Mohamed-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Katja Weinacht-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Kevin Quann-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Lee-Kai Sun-24627 (PDF Format)
Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Jufang Chang-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Lydia Lee-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Meixian Huang-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Varsha Sundaresan-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Yusuke Ito-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Zhiliang Bai-24629 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Ivan Cohen-24628 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Jan Mueller-24628 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Mohammad Alhomoud-24628 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Hongwei Ren-24631 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Jingyu Xiang-24631 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Puneeth Guruprasad-24631 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers James Kuzich-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jay Daniels-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jort Van Der Schans-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Kathryn Cappell-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Mathew Angelos-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Zhenlong Li-24633 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Benjamin Goldenson-24630 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Catherine Danis-24630 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Corynn Kasap-24630 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Mylinh Bayle-24630 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Sergio Rutella-24630 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies (Video TS Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Janaki Manoja Vinnakota-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Ruchi Patel-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Shinpei Harada-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Stefanie Bachl-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Taisuke Kondo-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Yongxian HU-24632 (PDF Format)
Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights (Video TS Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Aibin Liang-24634 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Jens Hillengass-24634 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Matthew Frigault-24634 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Nirav Shah-24634 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas (Video TS Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Anand Bhagwat-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Claire Roddie-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Elizabeth Lihua Budde-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Fabian Mueller-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Peihua Lu-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Susan Bal-24637 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies (Video TS Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Jae Park-24636 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Julio Chavez-24636 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Lei Yu-24636 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Pierre Sesques-24636 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Robert Weinkove-24636 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies (Video TS Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Arjan van de Loosdrecht-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Armin Ghobadi-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Jessica Liegel-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Nirali Shah-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Samer Srour-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Yago Nieto-24635 (PDF Format)
Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas (Video TS Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Adam Kittai-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Alison Sehgal-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Andre Goy-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Jennifer Crombie-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Michael Cook-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Swetha Kambhampati-24638 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data (Video TS Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Anna Ossami Saidy-24639 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Evandro Bezerra-24639 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Gregory Roloff-24639 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Jay Spiegel-24639 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Surbhi Sidana-24639 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas (Video TS Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Kai Rejeski-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Karthik Nath-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Mark Hamilton-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Matthew Frigault-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Roni Shouval-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Zimu Gong-24640 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity (Video TS Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Ash Alizadeh-24641 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Gloria Iacoboni-24641 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Katie Maurer-24641 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Mike Mattie-24641 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Sandeep Raj-24641 (PDF Format)
Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors (Video TS Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Daisuke Araki-24642 (PDF Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Kate Markey-24642 (PDF Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Laurent Garderet-24642 (PDF Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Natalie Holl-24642 (PDF Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Yi-Jiun Su-24642 (PDF Format)
Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells (Video TS Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Amado Karduss-24644 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Biqi Zhou-24644 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Filippo Milano-24644 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Reem Alasbali-24644 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Simona Piemontese-24644 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool (Video TS Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Andrew Artz-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anita Lawitschka-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anthony Sabulski-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Eric Davis-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Madhavi Lakkaraja-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Michael Grimley-24643 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications (Video TS Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Arpita Gandhi-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hannah Choe-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hao Zheng-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Ibrahim Yakoub-Agha-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Marie Robin-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Xiaoyu Zhang-24646 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies (Video TS Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Bertram Glass-24645 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Caspian Oliai-24645 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Issa Khouri-24645 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Krzysztof Kalwak-24645 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Rajni Agarwal-24645 (PDF Format)
Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia (Video TS Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Alina Markova-24647 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Jeffery Auletta-24647 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Nikolaos Spyrou-24647 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Yu Akahoshi-24647 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Zachariah Defilipp-24647 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management (Video TS Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Erik Thiele Orberg-24648 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Haowen Xiao-24648 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Leslie Kean-24648 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Michael Martens-24648 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Xiaoxuan Lai-24648 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology (Video TS Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Corey Cutler-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Hang Zhang-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Nicoletta Cieri-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Ramzi Abboud-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Robert Zeiser-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Zachariah Defilipp-24649 (PDF Format)
Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment (Video TS Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Alexandria Maurer-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Dustin McCurry-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Hengwei Wu-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Luca Vago-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Nicoletta Cieri-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Shahinaz Gadalla-24651 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes (Video TS Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Arnon Nagler-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mary Eapen-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mazin Mohamed Abdulsalam-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Rohtesh Mehta-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Sitong Chen-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Zhihui Li-24650 (PDF Format)
Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations (Video TS Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Gordon Cook-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach June-Wha Rhee-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Leyre Bento-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Marc-Andrea Baertsch-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Mazyar Shadman-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Shohei Mizuno-24652 (PDF Format)
Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach (Video TS Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Arnon Nagler-24653 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Johannes Schetelig-24653 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Juan Montoro-24653 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Minoru Kanaya-24653 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Rohtesh Mehta-24653 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection (Video TS Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Ali Bazarbachi-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Shernan Holtan-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Simona Pagliuca-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Timothy Voorhees-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yuho Najima-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yves Chalandon-24655 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation (Video TS Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Ali Bazarbachi-24654 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Benjamin Huang-24654 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Iman Abou Dalle-24654 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Zaid Abdel Rahman-24654 (PDF Format)
Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification (Video TS Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Alok Srivastava-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside John DiPersio-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Naoya Uchida-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Simon Chu-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Stefan Radtke-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Vincent Muczynski-24657 (PDF Format)
Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside (Video TS Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Franco Locatelli-24656 (PDF Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Haydar Frangoul-24656 (PDF Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Julie Kanter-24656 (PDF Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Steven Pipe-24656 (PDF Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Ulrike Reiss-24656 (PDF Format)
Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders (Video TS Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Anna Montanaro-24658 (PDF Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Chao-Yie Yang-24658 (PDF Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Lukas Kazianka-24658 (PDF Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Monika Toma-24658 (PDF Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Samuel Taylor-24658 (PDF Format)
Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders (Video TS Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Arda Durmaz-24659 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Chorom Pak-24659 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Jurik Mutter-24659 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Yoonkyu Lee-24659 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology (Video TS Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Andrew Srisuwananukorn-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Anna Kamysheva-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Catherine Lecat-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Chen Zhou-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Gianluca Asti-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Yoko Kawamura-24660 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology (Video TS Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Francisco Marchi-24661 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Gianluca Asti-24661 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Jing Sun-24661 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Vikram Dhillon-24661 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Zhongxun Shi-24661 (PDF Format)
Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology (Video TS Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Ashish Gupta-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Cecily Allen-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Costa Kazadi-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Lucy Fox-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Shiliang Ge-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Steven Hardy-24664 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology (Video TS Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Charles Jonassaint-24662 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Kim Smith-Whitley-24662 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Layla Van Doren-24662 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Pranav Shrestha-24662 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Robyn Cohen-24662 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education (Video TS Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Chiara Alessandra Cella-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Ming Y Lim-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Neha Bhasin-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Richard Godby-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Sara Mancuso-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Stacey Fedewa-24663 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders (Video TS Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Erica Mamauag-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ifeyinwa Osunkwo-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Julie Kanter-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ofelia Alvarez-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Wally Smith-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Yogindra Persaud-24665 (PDF Format)
Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum (Video TS Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Aaron Cohen-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Arti Vaishnav-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Laura Quillen-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Mia Djulbegovic-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Pallavi Ganguli-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Sikander Ailawadhi-24666 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias (Video TS Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Atharva Karulkar-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Matthew Gromowsky-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Meng-Hsuan Lin-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Patrick Connor Johnson-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Radhika Bansal-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Tonya Cox-24668 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy (Video TS Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Andrew Hantel-24667 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Chieh Yang-24667 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Jing-Zhou Hou-24667 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Ludovic Fouillet-24667 (PDF Format)
Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data (Video TS Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christa Meyer-24669 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christopher Su-24669 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Marissa Locastro-24669 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Pamela Egan-24669 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Thomas Walsh-24669 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies (Video TS Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Ashley Hadjis-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Christopher Strouse-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Danielle McQuinn-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Eshana Shah-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Jaime Preussler-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Rahul Mishra-24670 (PDF Format)
Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies (Video TS Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Andrew Kuykendall-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jiasen He-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jordan Schaefer-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Josue Marquez-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Justine Ryu-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Ummul Asfeen-24672 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients (Video TS Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Charity Oyedeji-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Joseph Walden-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Kim Agrippa-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Oliver Shastri-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Rajagopalan Subramaniam-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Seethal Jacob-24671 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease (Video TS Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Antonio Risitano-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders George Goshua-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Nora Gibson-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Satoko Ito-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Shoshana Revel-Vilk-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Vincent Ho-24673 (PDF Format)
Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma David Cordas dos Santos-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Francesco Marchesi-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Ghulam Rehman Mohyuddin-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Rahul Banerjee-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Roberto Mina-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Shakira Grant-24677 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Adam Kittai-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Amber Koehler-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Andres Noyola-Perez-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Maria Fernandez Turizo-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Rockbum Kim-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Vaishali Dulobdas-24678 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data David Leaf-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Kimberly Saverno-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Mazyar Shadman-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Narendranath Epperla-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Nilanjan Ghosh-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Pere Barba-24675 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Alissa Visram-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Doris Hansen-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Fieke Hoff-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Hira Mian-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Inger Nijhof-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Meera Mohan-24674 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Amy Wang-24676 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Annalynn Williams-24676 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Benoit Tessoulin-24676 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Guillaume Cartron-24676 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Timothy OConnor-24676 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies (Video TS Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Gin Yi Lee-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Jorge Florindez-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Kaitlin Annunzio-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Mustafa Wasifuddin-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Narendranath Epperla-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Niloufer Khan-24679 (PDF Format)
Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma (Video TS Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Alice Mims-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Amer Zeidan-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Caitlin Elgarten-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Diego Adrianzen Herrera-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Emanuele Angelucci-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Nosakhare Ilerhunmwuwa-24682 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes (Video TS Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Alma Habib-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Daniel Zheng-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Jeffrey Rubnitz-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michael Grunwald-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michelle Lee-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Teresa Caprice-24681 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities (Video TS Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Areej El-Jawahri-24680 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Diego Adrianzen Herrera-24680 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Esther Oliva-24680 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Kirollos Hanna-24680 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Valeria Santini-24680 (PDF Format)
Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies (Video TS Format)
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Linde Miles-24146 (PDF Format)
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Mark Dawson-24146 (PDF Format)
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Seishi Ogawa-24146 (PDF Format)
Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies (Video TS Format)
Scientific Program Emerging Methodologies to Investigate Platelet Biology Andrew Johnson-24144 (PDF Format)
Scientific Program Emerging Methodologies to Investigate Platelet Biology Anita Eckly-24144 (PDF Format)
Scientific Program Emerging Methodologies to Investigate Platelet Biology Florian Gaertner-24144 (PDF Format)
Scientific Program Emerging Methodologies to Investigate Platelet Biology (Video TS Format)
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Demin Wang-24150 (PDF Format)
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Rick Kapur-24150 (PDF Format)
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Satheesh Chonat-24150 (PDF Format)
Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine (Video TS Format)
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Dachuan Zhang-24143 (PDF Format)
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Leon Kautz-24143 (PDF Format)
Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis (Video TS Format)
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Alexander Marson-24142 (PDF Format)
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Carl June-24142 (PDF Format)
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Chiara Bonini-24142 (PDF Format)
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Dan Kaufman-24142 (PDF Format)
Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy (Video TS Format)
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Aswin Sekar-24139 (PDF Format)
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Laura Pasqualucci-24139 (PDF Format)
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Mandeep Singh-24139 (PDF Format)
Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (Video TS Format)
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Alan Cantor-24145 (PDF Format)
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Anna Beaudin-24145 (PDF Format)
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Shannon McKinney-Freeman-24145 (PDF Format)
Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood (Video TS Format)
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Alyssa Kennedy-24137 (PDF Format)
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Jean Soulier-24137 (PDF Format)
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Sushree Sahoo-24137 (PDF Format)
Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes (Video TS Format)
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Evi Stavrou-24149 (PDF Format)
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Ioannis Mitroulis-24149 (PDF Format)
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Kimberly Martinod-24149 (PDF Format)
Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis (Video TS Format)
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Jeroen Eikenboom-24141 (PDF Format)
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Leah Sabin-24141 (PDF Format)
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Lindsey George-24141 (PDF Format)
Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders (Video TS Format)
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Jordan Shavit-24136 (PDF Format)
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Pavel Davizon-Castillo-24136 (PDF Format)
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Suzan Williams-24136 (PDF Format)
Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome (Video TS Format)
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Daniel Lucas-Alcaraz-24140 (PDF Format)
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Maria Carolina Florian-24140 (PDF Format)
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Tiago Luis-24140 (PDF Format)
Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis (Video TS Format)
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Elham Azizi-24138 (PDF Format)
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Fei Chen-24138 (PDF Format)
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Rong Fan-24138 (PDF Format)
Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology (Video TS Format)
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Eugenio Morelli-24147 (PDF Format)
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Marta Chesi-24147 (PDF Format)
Scientific Program The Evolution of Multiple Myeloma From Inside-Out Tom Cupedo-24147 (PDF Format)
Scientific Program The Evolution of Multiple Myeloma From Inside-Out (Video TS Format)
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Ann Dean-24148 (PDF Format)
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Gerd Blobel-24148 (PDF Format)
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Mitchell Weiss-24148 (PDF Format)
Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression (Video TS Format)
Scientific Symposia Alternative Immune Effector Cells Evan Weber-24835 (PDF Format)
Scientific Symposia Alternative Immune Effector Cells James Cronk-24835 (PDF Format)
Scientific Symposia Alternative Immune Effector Cells Marie Bleakley-24835 (PDF Format)
Scientific Symposia Alternative Immune Effector Cells (Video TS Format)
Scientific Symposia Multi-Omics Driven Precision Hematology Jun J. Yang-24836 (PDF Format)
Scientific Symposia Multi-Omics Driven Precision Hematology Mika Kontro-24836 (PDF Format)
Scientific Symposia Multi-Omics Driven Precision Hematology Pamela Becker-24836 (PDF Format)
Scientific Symposia Multi-Omics Driven Precision Hematology (Video TS Format)
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Caterina Casari-24833 (PDF Format)
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Matthew Flick-24833 (PDF Format)
Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis (Video TS Format)
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Ami Smith-24834 (PDF Format)
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Kate Markey-24834 (PDF Format)
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Marcel van den Brink-24834 (PDF Format)
Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies (Video TS Format)
Scientific Symposia Understanding Sickle Cell Pathophysiology Enrico Novelli-24837 (PDF Format)
Scientific Symposia Understanding Sickle Cell Pathophysiology Jeffrey Chalmers-24837 (PDF Format)
Scientific Symposia Understanding Sickle Cell Pathophysiology Lucia De Franceschi-24837 (PDF Format)
Scientific Symposia Understanding Sickle Cell Pathophysiology (Video TS Format)
Special-Interest Sessions 2023 ASH Guideline Implementation Champions Christina Ruiz-24365 (PDF Format)
Special-Interest Sessions 2023 ASH Guideline Implementation Champions Gabriella Nguyen-24365 (PDF Format)
Special-Interest Sessions 2023 ASH Guideline Implementation Champions (Video TS Format)
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Torsten Haferlach-24388 (PDF Format)
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Weida Tong-24388 (PDF Format)
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Yates Coley-24388 (PDF Format)
Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 (Video TS Format)
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Alessandra Ferrajoli-24366 (PDF Format)
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Ayman Alhejazi-24366 (PDF Format)
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Vilmarie Rodriguez-24366 (PDF Format)
Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions (Video TS Format)
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Aaron Goodman-24159 (PDF Format)
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Benjamin Tillman-24159 (PDF Format)
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients David Andorsky-24159 (PDF Format)
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Shannon Walker-24159 (PDF Format)
Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients (Video TS Format)
Special-Interest Sessions ASH Grassroots Network Lunch (Video TS Format)
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Julie Wolfson-24153 (PDF Format)
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Sumit Gupta-24153 (PDF Format)
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Wendy Stock-24153 (PDF Format)
Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (Video TS Format)
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Deborah Siegal-24152 (PDF Format)
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Saskia Middeldorp-24152 (PDF Format)
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Suely Rezende-24152 (PDF Format)
Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New (Video TS Format)
Special-Interest Sessions Blood and Beyond (Video TS Format)
Special-Interest Sessions Junior Faculty Career Development Session Cassandra Josephson-24155 (PDF Format)
Special-Interest Sessions Junior Faculty Career Development Session Oyebimpe Adesina-24155 (PDF Format)
Special-Interest Sessions Junior Faculty Career Development Session Srinivas Devarakonda-24155 (PDF Format)
Special-Interest Sessions Junior Faculty Career Development Session (Video TS Format)
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Alison Loren-24158 (PDF Format)
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Erica Marsh-24158 (PDF Format)
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Mindy Christianson-24158 (PDF Format)
Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care (Video TS Format)
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Alisa Wolberg-24154 (PDF Format)
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Nicole Gormley-24154 (PDF Format)
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Saad Usmani-24154 (PDF Format)
Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community (Video TS Format)
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Alexis Leonard-24422 (PDF Format)
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Julie Kanter-24422 (PDF Format)
Special-Interest Sessions Special Session on Sickle Cell Disease Centers Sophie Lanzkron-24422 (PDF Format)
Special-Interest Sessions Special Session on Sickle Cell Disease Centers (Video TS Format)
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Alexandra Power-Hays-24151 (PDF Format)
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Allison Burnett-24151 (PDF Format)
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Geoffrey Barnes-24151 (PDF Format)
Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care (Video TS Format)
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Sandhya Panch-24367 (PDF Format)
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Surbhi Shah-24367 (PDF Format)
Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation (Video TS Format)
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ludmila Prokunina-Olsson-24831 (PDF Format)
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ryan Morin-24831 (PDF Format)
Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma (Video TS Format)
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Deborah Siegal-24130 (PDF Format)
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Sam Schulman-24130 (PDF Format)
Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors (Video TS Format)
Spotlight Sessions Immunometabolism as a Tool to Advance Cell Therapy (Video TS Format)
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Paolo Ghia-24131 (PDF Format)
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Zhuoer Xie-24131 (PDF Format)
Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL (Video TS Format)
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Srinivas Devarakonda-24830 (PDF Format)
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Yvonne Efebera-24830 (PDF Format)
Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients (Video TS Format)
Spotlight Sessions The Mysteries of Factor XI David Gailani-24832 (PDF Format)
Spotlight Sessions The Mysteries of Factor XI Ophira Salomon-24832 (PDF Format)
Spotlight Sessions The Mysteries of Factor XI (Video TS Format)
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution John Mark Sloan-24128 (PDF Format)
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Lauren Merz-24128 (PDF Format)
Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution (Video TS Format)
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Justin Taylor-24132 (PDF Format)
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Valeria Santini-24132 (PDF Format)
Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials (Video TS Format)
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Carlos Ramos-24129 (PDF Format)
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Jonathan Fisher-24129 (PDF Format)
Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes (Video TS Format)
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Amber Yates-24862 (PDF Format)
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Timothy Kubal-24862 (PDF Format)
Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia (Video TS Format)
Trainee Didactic Session Show Me the Money – Funding Your Research Cassandra Josephson-24865 (PDF Format)
Trainee Didactic Session Show Me the Money – Funding Your Research Ifeyinwa Osunkwo-24865 (PDF Format)
Trainee Didactic Session Show Me the Money – Funding Your Research (Video TS Format)
Trainee Didactic Session The International Trainee Journey Andres Gomez-De Leon-24160 (PDF Format)
Trainee Didactic Session The International Trainee Journey Eloisa Riva-24160 (PDF Format)
Trainee Didactic Session The International Trainee Journey (Video TS Format)
Trainee Didactic Session What to Ask For in an Interview Alison Walker-24867 (PDF Format)
Trainee Didactic Session What to Ask For in an Interview (Video TS Format)